BriaCell presents Bria-IMT phase 2 survival data in metastatic breast cancer
BCTX•BriaCell reported median overall survival of 16.6 months in Phase 2 with the Phase 3 formulation and treatment sequence. Median progression-free survival was 3.6 months with the selected formulation versus 2.6 months with the alternative.




